

Papillary thyroid carcinoma in a mother and child evolving after the manifestation of Graves' disease


AL Badi, M^{*1}; Lankes, E^{*2}; Schmid, KW⁴; Kuehnen, P³; AL Senani, A¹; Krude, H³; Biebermann, H³; Grueters, A²

¹National Diabetes and Endocrine Centre, Royal Hospital, Muscat, Oman, ²Dept of Pediatric Endocrinology, Charité, Berlin, Germany, ³Institute for Experimental Pediatric Endocrinology, Charité, Berlin, Germany, ⁴University Hospital Essen, Germany, ^{*}shared first coauthors

OBJECTIVES

Large familial papillary thyroid carcinoma (PTC) in childhood has been described only in single cases, mainly in the context of rare syndromes (e.g APC-associated-syndrome, PTEN-hamartoma syndromes). Small PTC in Graves' disease (GD) has been described in adults¹, but not in familial cases including young children. PTC in GD seems to be more aggressive². We investigated the association of large metastatic PTC in a 10 years old girl and her mother evolving rapidly in both of them after the manifestation of GD. A genetic basis for the non-syndromic familial GD and PTC in a background with a high prevalence of PTC in adults GD was suspected.

Patient History



The mother:

Manifestation **Graves' disease** (TSH-R AB positive) 2014: initiation of antithyroid drug treatment with carbimazole

3 months later:

detection of a large nodule, **PTC**, one LN metastasis, → ablative thyroid surgery, radioiodine treatment

The patient:

Manifestation **Graves' disease** (TSH-R AB positive) 2015:

- loss of 10 kg BW
 - tachycardia
 - prominent eyes
- initiation of antithyroid drug treatment with carbimazole

3 months later:

detection of a large nodule, **PTC**, one LN metastasis, → ablative thyroid surgery, radioiodine treatment


Results

Imaging studies:

The ultrasound studies revealed a 1,2 x 2,3 cm large nodule in the right lobe and the thyroid with an echostructure compatible with autoimmune thyroid disease and increased perfusion. (**Fig 1/2/3**) Scintigraphy revealed an increased uptake (**Fig 4**), thus the nodule was not visible.

Histopathology:

16 mm PTC with several lymph node metastases (pT1bpN1b(9/10)R0L0V0) in a thyroid with chronic interstitial inflammation



Genetic studies:

No somatic variants were found for APC 1-16; DDR2 15; DICER1 1-28; EGFR 18-21; ERBB2 5,6,15,20,23,29; FGFR1,3, 7, 13, 17, 18; HRAS 2-4; KIT 9-11, 13, 17, 18; KRAS 2-4; MET 3, 8, 11, 14, 19; NRAS 2; PDGFR 12, 14, 18; PIK3CA 3, 5, 10, 16, 21; PRKAR1A 1-11, PTEN 1-9; RAF/11; RET 0, 11, 13-16; TP53 4-9;

Variants:

1. BRAF-Mutation (V600E)

2. TSH-R Exon 1 mutation: rs2239610 c.154C>A p.Pro52Thr

3. TSH-R Exon 10 variant: c1377G>A; p.=Ala) no AA change

Family Member	Exon 1 rs2239610 c.154C>A p.Pro52Thr
Patient	CA
Mother	CA
Brother 1	AA
Brother 2	CA
Sister 1	CA
Sister 2	CA

References

- 1 Stocker DJ, Burch HB Minerva Endocrinol 2003; 28:205–12
- 2 Pellegriti G et al J Clin Endocrinol Metab 2013;98:1014–21
- 3 Kunjumohamed FP et al, Saudi Med Journal 2015; 36: 874-877
- 4 Pohl M et al J Clin Pathol. 2016 Jul 1 pii: jclinpath-2016-203739

Conclusions

A rare association of GD and PTC in a mother and her daughter was associated with BRAF V600E in the tumor tissue. A TSH-receptor variant in Exon 1 was found also in the two sisters with cystic abnormalities in ultrasound studies. Since a high prevalence of PTC associated with GD is known in the ethnic background³ of the family, a further genetic work-up has been initiated, to find out if this rare association could be caused by a genetic predisposition in thyroid structure or function.

Alternatively an expression of a microRNA caused by an increase in proliferation⁴, by a genetic variant of the immune system, an environmental factor or the antithyroid drug treatment may have triggered the development of the PTC.







Figure 1 and Figure 2 : Ultrasound studies of the visible nodule

Figure 3: Doppler ultrasound study

Figure 4: ⁹⁹Technitium uptake study

